Özet:

Introduction and Target: Biological agents provide effective control of disease activity in patients with chronic inflammatory disease (CEH). However, they are associated with an increased risk of serious infection. The aim of this study is to investigate the distribution and risk of serious infections in patients using a biological agent, the recommended screening tests and vaccination rates in these patients. Methods and Requirements: We reverse assessments of patients with HIV in the biological agent; we reviewed hepatitis and tuberculosis (TB) screening tests and recommended vaccines, serious infection rates and risk factors. Results: 58% of the 320 patients involved in the study were men and an average age of 44.5 (±12.2). Distribution of the biological agents used by patients; Infliksimab 108 (33.8%) and Adalimumab 115 (35%) 9), Etanercept 61 (%19.1), Ustekinumab 19 (%5.9), Sertolizumab 9 (%2.8), Golimumab 5 (%1.6) and Sekukinumab 3 (%0.9). The rates of vaccination for hepatitis B, pneumococcus, flu and hepatitis A were 82.9 per cent, 12.5 per cent, 11.6 per cent and 4 per cent respectively. As a TB screening test, 33.4 percent of patients received a tuberculosis skin test and 79 percent received a QuantiFERON-TB Gold test. A total of 25 (7.8%) of severe infections occurred and the most common area of infection was the respiratory (28) and urinary (28) pathways. The double logistical regression analysis showed that patients with chronic obstructive lungs disease (KOAH) and who are using azathioprin had a significantly higher risk of infection. The most common infectious areas were the respiratory and urinary tract, and the risk of infection was significantly increased in patients with KOAH and using azathioprin. Vaccination rates for KEH patients were lower than recommended. Patients using a biological agent were aware that the risk of hepatitis B and TB reactivation was higher than other infections.

Anahtar Kelimeler: